Biodesix Q3 Revenue Misses, Full-Year 2026 Guidance Cut to $101M-$103M
BDSX has more than doubled off its 52-week low of $5.26.
Summary
Biodesix posted Q3 revenue of $24.0 million, about 13% below the $27.5 million estimate, and cut full-year 2026 revenue guidance to $101 million-$103 million. Management blames sales-rep staffing and project timing, not demand, and points to a stronger October.
Updates
· Benzinga — Biodesix shares fell 29.44% to $14 in after-hours trading after the Q3 revenue miss and guidance cut.
Key Events · Earnings and Guidance · BDSX
-
Q3 Revenue Misses Consensus
Total revenue of $24.041 million rose 10% year over year but fell roughly 13% short of the $27.5 million IBES estimate.
-
Full-Year Guidance Cut
2026 revenue outlook revised to $101 million-$103 million, with the midpoint representing approximately 15% growth over 2025, reflecting Q3 results, sales team expansion timing, and delayed Development Services contracts.
-
Diagnostic Testing Still Growing
Diagnostic Testing revenue of $23.055 million grew 16% on a 24% increase in test volumes to 19,400, partly offset by lower average revenue per test as Nodify CDT made up a larger share of lung volume.
-
Losses Narrow, Cash Tightens
Net loss of $8.032 million improved 8% and Adjusted EBITDA loss of $3.860 million improved 16% year over year; cash was $28.409 million at September 30, down $1.6 million in the quarter after $6.3 million of net ATM proceeds.
Analysis · BDSX · Industrial Applications And Services
Biodesix grew Q3 revenue 10% to $24.0 million, but that landed roughly 13% below the $27.5 million consensus estimate, and management cut full-year 2026 revenue guidance to $101 million-$103 million. The shortfall was execution and timing, not demand: fewer sales reps than planned, heavier primary-care seasonality, and delayed Development Services projects. The company says it has added sales capacity and October was its strongest new-physician acquisition month this year, but the burden of proof now sits on Q4 execution. Cash of $28.4 million, down $1.6 million in the quarter after $6.3 million of ATM proceeds, leaves limited room for another miss.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDSX was trading at $18.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $5.26 to $31.97. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.